Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

New BSR guidelines on prescribing anti-rheumatic medication during pregnancy, breastfeeding

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Guselkumab drug more effective than current standard of care for psoriasis

Guselkumab drug more effective than current standard of care for psoriasis

Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

3SBio obtains ex-China global rights to Apexigen's anti-TNF mAb technology

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Study indicates that arthritis patients may not be taking medication as regularly as prescribed

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Mundipharma launches Remsima® (infliximab), a new-generation value-based monoclonal antibody, in six European markets

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Australian Prescriber publishes top 10 subsidised drugs in Australia

Australian Prescriber publishes top 10 subsidised drugs in Australia

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation identified as potential anti-TNF response biomarker for RA

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients